{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:26:25Z","timestamp":1767986785254,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Durvalumab is a PD\u2010L1 inhibitor that triggers a blockade resulting in enhanced anti\u2010tumor responses related to increased T\u2010cell activation. There is potential for numerous immune\u2010related adverse events (irAEs) with this treatment, most of which have been shown to be effectively managed with high\u2010dose steroids. Immunotherapy\u2010related gastritis, while rare compared to other irAEs is an emerging concern as the use of immune checkpoint inhibitors (ICIs) increases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>This case study examines a 66\u2010year\u2010old female with extensive\u2010stage small cell lung cancer (ES\u2010SCLC) treated with durvalumab, alongside chemotherapy. Twenty\u2010three months into treatment, she developed non\u2010specific gastrointestinal (GI) symptoms including abdominal pain, appetite loss, and significant weight loss. Despite conservative management, resolution only occurred following the use of high\u2010dose steroids, a finding consistent with immunotherapy\u2010related gastritis. The patient then went onto a successful rechallenge of immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case represents the first report on the rare occurrence of immune\u2010related gastritis in an ES\u2010SCLC patient who has been on immunotherapy for nearly 2\u2009years. Current literature is limited in the understanding of underlying mechanisms of PD\u2010L1\u2010related irAEs and optimal management strategies for rare toxicities like gastritis in immunotherapy\u2010treated cancer patients. This report aims to address the unmet need for further research on rare toxicities to immunotherapy in unique cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70422","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:08:33Z","timestamp":1764720513000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy\u2010Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab\u2014A Case Report"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2213-456X","authenticated-orcid":false,"given":"Marc C.","family":"Cavaliere","sequence":"first","affiliation":[{"name":"McMaster University  Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6244-8335","authenticated-orcid":false,"given":"Silvana","family":"Spadafora","sequence":"additional","affiliation":[{"name":"Algoma District Cancer Program  Sault Ste Marie Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-7773","authenticated-orcid":false,"given":"Michela","family":"Febbraro","sequence":"additional","affiliation":[{"name":"Algoma District Cancer Program  Sault Ste Marie Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211028570"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010146"},{"key":"e_1_2_11_4_1","volume-title":"Small Cell Lung Cancer Stages","author":"American Cancer Society","year":"2024"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112393"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd\u201021\u2010388"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920021"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.6163"},{"key":"e_1_2_11_9_1","volume-title":"Durvalumab Drug Monograph","author":"Cancer Care Ontario","year":"2025"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(19)32222\u20106"},{"key":"e_1_2_11_11_1","volume-title":"Drug Formulary: Carboplatin\u2010Etoposide\u2010Durvalumab","author":"Cancer Care Ontario","year":"2023"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101174"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34543"},{"key":"e_1_2_11_15_1","volume-title":"Management of Immune\u2010Related Diarrhea\/Colitis","author":"Cancer Care Ontario","year":"2017"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez308"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2408852"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad031"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.636"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328\u2010021\u201001582\u20105"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.22975"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840916"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i18.4350"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46392"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8292\u201021"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101896"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20101839\u20104303"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa081"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:45:52Z","timestamp":1766508352000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cnr2.70422"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70422","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70422"}}